Oncologie

, Volume 10, Issue 9, pp 525–528

Prise en charge oncologique du patient opéré: chimiothérapie adjuvante, surveillance, traitement des rechutes

Synthèse / Review Article

Résumé

Malgré les progrès thérapeutiques récents, obtenus avec la chimiothérapie périopératoire, en particulier démontrés par les essais de chimiothérapie adjuvante, les rechutes après chirurgie d’un carcinome bronchique non à petites cellules restent fréquentes. Les efforts de recherche se pousuivent dans le cadre des traitements adjuvants, avec des essais intégrant les thérapeutiques ciblées et évaluant des stratégies thérapeutiques personnalisées. D’autres questions n’ont actuellement aucune réponse et font l’objet d’essais cliniques conduits sous l’égide de l’IFCT, tels que la radiothérapie postopératoire des N2, la surveillance et le traitement des rechutes. La surveillance après chirurgie ± chimiothérapie, bien que théoriquement susceptible d’améliorer la survie par une détection plus précoce des rechutes, ne repose actuellement sur aucune donnée scientifique solide. Avec l’avènement des chimiothérapies périopératoires, le profil des rechutes est susceptible de se modifier, et la meilleure chimiothérapie à délivrer lors de rechutes métastatiques reste à définir.

Mots clés

Carcinome bronchique non à petites cellules Chirurgie Chimiothérapie adjuvante Surveillance Rechute 

Oncological management of the operated patient: adjuvant chemotherapy, surveillance, treatment of recurrences

Abstract

Despite recent progress obtained from perioperative chemotherapy and particularly, that demonstrated by the clinical trials on adjuvant chemotherapy, recurrences remain frequent after surgery for non-small cell lung cancer. Research on adjuvant treatments is ongoing, focused on targeted therapies or personalised therapeutic strategies. Other questions remain unanswered and are still investigated in clinical trials by the French Cancer Institute, such as thoracic radiotherapy for N2 disease, surveillance and treatment of recurrences. Although post-surgical surveillance, with or without chemotherapy, may theoretically increase survival by an earlier detection of recurrences, there are no evidence-based data. With the wide use of adjuvant chemotherapy, the profile of recurrences is likely to change and the best chemotherapy for metastatic recurrences remains to be defined.

Keywords

Non-small cell lung cancer Surgery adjuvant chemotherapy Follow-up Recurrence 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Dautzenberg B, Arriagada R, Chammard AB, et al. (1999) A controlled study of postoperative radiotherapy for patients with completely resected non-small cell lung carcinoma. Cancer 86: 265–273PubMedCrossRefGoogle Scholar
  2. 2.
    Douillard JY, Rosell R, De Lena M, et al. (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7(9): 719–727PubMedCrossRefGoogle Scholar
  3. 3.
    Gilbert S, Reid KR, Lam MY, Petsikas D (2000) Who should follow-up lung cancer patients after operation? Ann Thorac Surg 69(6): 1696–1700PubMedCrossRefGoogle Scholar
  4. 4.
    Ichinose Y, Kato H, Koike T, et al., Japan Clinical Oncology Group (2001) Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer 34: 29–36PubMedCrossRefGoogle Scholar
  5. 5.
    International Adjuvant Lung cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350: 351–360CrossRefGoogle Scholar
  6. 6.
    Keller SM, Adak S, Wagner H, et al., for the Eastern Cooperative Oncology Group (2000) A randomised trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small cell lung cancer. N Engl J Med 343: 1217–1222PubMedCrossRefGoogle Scholar
  7. 7.
    Lally BE, Zelterman D, Colasanto JM, et al. (2006) Postoperative radiotherapy for stage II or III non-small cell lung cancer using the surveillance epidemiology and end results database. J Clin Oncol 24: 2998–3006PubMedCrossRefGoogle Scholar
  8. 8.
    Martini N, Melamed M (1975) Multiple primary lung cancers. J Thorac Cardiovasc Surg 70: 606–612PubMedGoogle Scholar
  9. 9.
    Non Small Cell Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899–909Google Scholar
  10. 10.
    Olaussen KA, Dunant A, Fouret P, et al. (2006) DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983–991PubMedCrossRefGoogle Scholar
  11. 11.
    Pfister DG, Johnson DH, Azzoli CG, et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 22(2): 330–353PubMedCrossRefGoogle Scholar
  12. 12.
    PORT Meta-analysis Trialists Group (1998) Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352: 257–263CrossRefGoogle Scholar
  13. 13.
    Rubins J, Unger M, Colice GL (2007) Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 132(Suppl 3): 355S–367SPubMedCrossRefGoogle Scholar
  14. 14.
    Scagliotti GV, Fossati R, Torri V, et al., for the ALPI/EORTC Cooperative Group Investigators (2003) Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J Nat Cancer Inst 95: 1453–1461PubMedGoogle Scholar
  15. 15.
    Stephens RJ, Girling DJ, Bleehen NM, et al., for the Medical Research Council Lung Cancer Working Party (1996) The role of postoperative radiotherapy in non-small cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1–T2, N1–N2, M0 disease. Br J Cancer 74: 632–639PubMedGoogle Scholar
  16. 16.
    Strauss G, Herndon J, Maddaus M, et al. (2006) Adjuvant chemotherapy in Stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 24: 7007 (annual meeting proceedings)Google Scholar
  17. 17.
    Tada H, Tsuchiya R, Ichinose Y, et al. (2004) A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 43: 167–173PubMedCrossRefGoogle Scholar
  18. 18.
    Virgo KS, McKirgan LW, Caputo MC, et al. (1995) Post-treatment management options for patients with lung cancer. Ann Surg 222(6): 700–710PubMedCrossRefGoogle Scholar
  19. 19.
    Waller D, Peake MD, Stephens RJ, et al. (2004) Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardio-Thorac Surg 26: 173–182CrossRefGoogle Scholar
  20. 20.
    Walsh GL, O’Connor M, Willis KM, et al. (1995) Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg 60(6): 1563–1570PubMedCrossRefGoogle Scholar
  21. 21.
    Westeel V, Choma D, Clément F, et al. (2000) Relevance of an intensive post-operative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg 70: 1185–1190PubMedCrossRefGoogle Scholar
  22. 22.
    Winton TL, Livingston R, Johnson D, et al. (2005) Vinorelbine plus cisplatin versus observation in resected non-small cell lung cancer. N Engl J Med 352: 2589–2597PubMedCrossRefGoogle Scholar
  23. 23.
    Younes RN, Gross JL, Deheinzelin D (1999) Follow-up in lung cancer: how often and for what purpose? Chest 115(6): 1494–1499PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag France 2008

Authors and Affiliations

  1. 1.Service de pneumologieuniversité de Franche-Comté, CHU, hôpital Jean-MinjozBesançonFrance
  2. 2.PMAC oncologie thoraciquecentre hospitalier universitaire de GrenobleGrenoble cedexFrance

Personalised recommendations